about
FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapyCDA: combinatorial drug discovery using transcriptional response modulesDose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver.Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on IrinotecCES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimenCurrent progress in pharmacogenetics.OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapyRelationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimensPredicting inhaled corticosteroid response in asthma with two associated SNPs.Clinical application of high throughput molecular screening techniques for pharmacogenomics.Dissecting the Effect of Genetic Variation on the Hepatic Expression of Drug Disposition Genes across the Collaborative Cross Mouse StrainsDMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.Improving oncology outcomes through targeted therapeutics will require electronic delivery systems.Transcriptional regulation and pharmacogenomics.Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine.Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis.Genomics and pharmacogenomics of pancreatic adenocarcinoma.Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis.Personalized medicine policy challenges: measuring clinical utility at point of care.Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications.Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rare ABCC2 polymorphism: a case report.Safety of palliative chemotherapy in advanced pancreatic cancer.Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients.Drug-induced hepatotoxicity in cancer patients - implication for treatment.Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.Role of pharmacogenetics in public health and clinical health care: a SWOT analysis.A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia.An experimental study to identify the potential role of pharmacogenomics in determining the occurrence of oxaliplatin-induced liver injury.Formulation design and evaluation of quantum dot-loaded nanostructured lipid carriers for integrating bioimaging and anticancer therapy.Regulation of carboxylesterase-2 expression by p53 family proteins and enhanced anti-cancer activities among 5-fluorouracil, irinotecan and doxazolidine prodrug.Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene.Comparison of inhibition capability of scutellarein and scutellarin towards important liver UDP-glucuronosyltransferase (UGT) isoforms.Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients.Prediction of Response to Irinotecan and Drug Toxicity Based on Pharmacogenomics Test: A Prospective Case Study in Advanced Colorectal CancerEffect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients.Effect of hesperidin on the pharmacokinetics of CPT-11 and its active metabolite SN-38 by regulating hepatic Mrp2 in rats.Start using a checklist, PRONTO: Recommendation for a standard review process for chemotherapy orders.The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis.Uridine 5'-diphospho-glucronosyltrasferase: Its role in pharmacogenomics and human disease.Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
P2860
Q26851060-4F2FA99F-CA1E-4C32-B5F7-3C6740ED6C58Q28482122-9962B38A-A87E-4FB3-B743-839DBAE12714Q33422964-4DD5D337-A777-492D-A3CC-C987BD727840Q33875931-4F4A7FC3-8D0B-4D53-94D9-7672D294A023Q34359039-76B4733A-B925-4E54-B1C3-86121C690F39Q34996898-BED1C9F0-898A-4D0D-8697-0A5165285564Q35678729-0D5E70F1-F22A-48F7-B7EA-CFCD84711AE1Q35887458-29EFA50F-BED5-4706-84B8-89843948E87DQ36210219-A855BE14-14B3-43CE-AF2D-09A77C5BB0DAQ36441517-F5DCA75F-B395-4779-B983-A5790D9B4D58Q37310023-B4AF21A2-DBB5-44F6-96A8-980A78479899Q37619866-D92EEEB0-8CA4-48BB-B39C-C54006F754D9Q37875079-02711787-FE15-499D-BE76-FED6F87EB0E6Q37880878-1E8F7C2E-A66E-42C3-B764-21A17EE557A7Q37899883-6B13EADA-D7A5-43E9-B4D9-2444C32FD39FQ37969220-4FE95105-1877-4749-A5A7-F3C9BD2120A8Q37970279-DB3F924C-1A00-4026-9C48-055BA043ED04Q38024277-19EF2788-33E5-466D-8F32-8D90CFDCBCA6Q38027568-BC085A09-B220-4118-A966-E49FE5366873Q38050315-34193CEE-6AAB-4FD9-AFE8-DFC700DD8F3FQ38136298-6D8CC6B8-EFE0-4400-A066-098E0535ED62Q38806041-D6703C8B-1455-4B56-B514-E13992D68DA4Q38835268-5EF6B8E2-4D25-40F2-89A1-45A824B2A91CQ38845891-9A8F7B12-2FF0-4709-8F33-6AD2D370703DQ38922471-BC65E42C-6738-4761-BCEC-FFC153D235A8Q38941642-E9ECA108-F648-452C-8DE1-48DCFF061056Q39106004-66AF54B0-F3A3-47B6-BBAE-37D3DA3BF22FQ39185727-619EAAC5-363E-4CCE-B336-7593692D6771Q39199013-4E465911-813C-43A6-A121-3524A81E3DD6Q39200965-6AFCD1D9-02D8-4EDD-A56D-7745E1F472F2Q42180652-986D6A9D-5515-4EF5-AC2A-C21AE0CC0598Q44653923-0CE74B3E-C4D5-46EB-B697-B78EFA2A1A0AQ45456321-92A6030F-3A52-480C-A8BB-4FAEB204CCC9Q47233437-5B86A9B8-7E42-464C-99D3-E9A94DBE520FQ50042411-690D0028-6145-4518-B5A7-6F6D99DC28B8Q51579192-9B03D902-04C9-4F45-89E7-5C43EF7F8314Q53125855-77B48317-CFD7-4147-BF71-94B36AA78927Q54486022-306E0F39-7757-400E-99C4-7BA457977311Q55146337-5BFF2856-7145-4987-9B4B-5C66D98152D5Q55518023-ACD376EE-D066-4C7D-A25E-8C37835BBBB8
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Irinotecan pharmacogenomics
@ast
Irinotecan pharmacogenomics
@en
Irinotecan pharmacogenomics
@nl
type
label
Irinotecan pharmacogenomics
@ast
Irinotecan pharmacogenomics
@en
Irinotecan pharmacogenomics
@nl
prefLabel
Irinotecan pharmacogenomics
@ast
Irinotecan pharmacogenomics
@en
Irinotecan pharmacogenomics
@nl
P2860
P3181
P356
P1433
P1476
Irinotecan pharmacogenomics
@en
P2093
Janelle M Hoskins
Sharon Marsh
P2860
P304
P3181
P356
10.2217/PGS.10.95
P407
P577
2010-07-01T00:00:00Z